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Abstract
Background: Little study of the extramammary finding of breast MRIs has been done with only descriptive work of
the prevalence of location and malignancy. The purpose of the present study was to assess the prevalence, the
location, and the imaging characteristics of the incidentally detected extramammary findings on breast MRI and to
determine potential malignant characteristics.
Methods: The study evaluated extramammary findings in 109 patients who underwent breast MRI for the staging
of breast cancer and for the follow-up of post-therapy. Prevalence, the location, clinicopathologic findings of breast
cancer size, metastasis, and MRI characteristics were evaluated retrospectively. Malignancy of extramammary
findings was determined based on the pathologic examinations and diagnostic images.
Results: One hundred forty-nine incidental findings were detected in 109 (4.6 %) of 2361 patients, and 69 cases
were confirmed or considered to be malignant. The most common site was the bone (43/149, 28.9 %) with
malignancy found in 30 (69.8 %) of 43 bone lesions. Less frequent tumor locations were the liver (22.1 %), lung
(21.5 %), pleura or chest wall (10.1 %), mediastinum (6.7 %), supraclavicular lymph nodes (LNs) (6.0 %), and others
(4.7 %). Findings of significant relevance with malignancy of the extramammary findings included bigger size of
breast cancer, presence of LN metastasis, and distant metastasis (P < 0.01). Lesions showing iso- or hypo signal
intensity (SI) on T2-weighted imaging (T2WI) (P = 0.000), contrast enhancement (P = 0.000), high SI on diffusion-
weighted imaging (DWI) (P = 0.049), low SI on apparent-diffusion-coefficient map relative to DWI (P = 0.000), and
multiplicity (P = 0.000) of the extramammary finding were significantly related to malignancy.
Conclusions: Extramammary findings on breast MRI are not rare. Clinicopathologic features of the breast cancer
and MRI features of extramammary findings could be useful in estimating the malignancy of the incidental
extramammary finding.
Background
MRI is well known for its high sensitivity in the detection
and evaluation of the extent of breast cancer [1–4]. With
the use of 3.0-T MRI, which improves signal-to-noise ratio
and provides better resolution than does 1.5-T MRI at the
same time, more specificity for evaluating the morphology
of the lesions was attained [5–7]. In the context of high
soft tissue contrast and spatial resolution, whole-body
MRI has higher sensitivity for detecting liver, bone, or
brain metastases in metastatic cancers such as breast
cancer [8, 9]. In breast cancer, whole-body MRI has shown
similar sensitivity for the detection of loco-regional
recurrence and distant metastasis as positron emission
tomography-computed tomography (PET-CT) [10].
When reading a breast MRI, evaluation of the breast
tissue, chest wall, skin, and axillary lymph nodes (LNs)
should be performed primarily. However, all other
anatomical structures in the field of view (FOV) such as
the neck, lung, mediastinum, spine, rib, sternum, and
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upper abdomen should not be overlooked because these
will be the potential site of metastasis. Dietzel et al. has
shown sufficient diagnostic accuracy detecting distant
metastasis by simply extending the FOV to the hyoid bone
and upper pelvis with a coronal sequence T2 half-Fourier
acquisition single-shot turbo spin-echo image [11].
Until now, there has been little study of the extramam-
mary finding of breast MRIs. Only descriptive work of
the prevalence of location and malignancy has been
made [1, 12–14].
The purpose of this article is to retrospectively assess
the frequency, location, and MRI imaging findings of
incidentally detected extramammary findings on breast
MRI and to evaluate MRI imaging characteristics that
may suggest malignant lesions.
Methods
Subjects
We retrospectively reviewed radiology reports of breast
MRI studies performed from 2009 to December 2013.
We reviewed a total 3296 images from 2361 patients
who had breast MRI for the staging of known breast
cancer or follow-up studies after systemic chemotherapy,
neoadjuvant chemotherapy, or post-operation. MRI im-
ages reporting any extramammary findings, other than
breast lesion, intramammary LNs, internal mammary
LNs, and axillary LNs, were included. If the same extra-
mammary finding was found on follow-up MRI, only the
initial MRI finding was analyzed and counted. Of the
2361 patients, a total of 155 findings of 114 patients
were found in the radiologic reports. Six findings were
excluded: two findings from two patients who had breast
MRI for screening and had no breast tumor; two find-
ings of a patient, who had breast MRI for malignancy of
unknown origin that was confirmed to be lymphoma;
and two findings of two patients, who had insufficient
diagnostic study to determine the malignancy of the
extramammary lesion.
A total of 109 patients with 149 extramammary findings
met the inclusion criteria and were included in the ana-
lysis. Of these 109 patients, 20 patients had breast MRI
for follow-up after operation (Breast Imaging Reporting
and Data System, or BI-RADS, category 2 or 3); 69 pa-
tients had MRI for known malignancy before surgery (BI-
RADS category 6); 13 patients had follow-up breast MRI
after systemic therapy (n = 7) and neoadjuvant chemo-
therapy (n = 6); and 7 patients had breast MRI for the
evaluation of the confirmed post-operative recurrence
(BI-RADS category 6).
MRI protocol
MR imaging was performed in a prone position using
a dedicated bilateral breast surface coil. Imaging with
a 3-T MRI system (Verio; Siemens Healthcare, Erlangen,
Germany) was obtained using the following sequences: (1)
an axial, turbo spin-echo T2-weighted-imaging (T2WI)
sequence with a TR/TE of 4530/93, a flip angle of 80°, 34
slices, an FOV of 320 mm, a matrix size of 576 × 403, 1
number of excitations (NEX), a slice thickness of 4 mm,
and an acquisition time of 2 min 28 s; (2) axial diffusion-
weighted imaging (DWI) with two sequences (i.e., single-
shot echoplanar image (ss-EPI) or readout segmented EPI
(rs-EPI)) (b values 0 and 750 s/mm2, TR/TE 9800/87 ms
and 5600/55 ms, respectively; FOV 340 × 117 mm and
360 × 180 mm, respectively; matrix size 192 × 82; slice
thickness 4 mm; acquisition time 2 min 47 s and 2 min
31 s, respectively; 5 readout segments for rs-EPI). Appar-
ent diffusion coefficient (ADC) maps were calculated
automatically by using MRI software from the DWI im-
ages; (3) pre- and post-contrast, axial T1-weighted flash
three-dimensional volumetric interpolated brain examin-
ation (VIBE) sequences with a TR/TE of 4.4/1.7, a flip
angle of 10°, a slice thickness of 1.2 mm, and an acquisi-
tion time of 1 min. The images were obtained before
and at 10, 70, 130, 190, 250, and 310 s after an injec-
tion of contrast agent gadolinium DTPA (Gd-DTPA,
0.1 mmol/kg Gadovist; Bayer Schering Pharma, Berlin,
Germany). Imaging performed with a 1.5-T MRI sys-
tem (Signa; GE Medical Systems; Milwaukee, WI,
USA) was conducted using the following sequences:
(1) axial, fat-suppressed, fast spin-echo T2WI (TR/TE
= 4000/85, a flip angle of 90°, 30 slices, an FOV of
240 mm, a matrix of 256 × 224, a NEX of 2, a 3-mm
slice thickness with a 0.1 mm slice gap, and an acqui-
sition time of 2 min 56 s); (2) axial DWI with single-
shot echo planar imaging (EPI) (b = 0 and 1000 s/mm2,
TR/TE = 6000/75, a FOV of 360 mm, a matrix of 128 ×
128, 2 NEX, a 4-mm slice thickness with a 1-mm slice
gap, and an acquisition time of 1 min 30 s); and (3) pre-
and post-contrast, axial spin-echo T1-weighted imaging
(T1WI) (TR/TE = 6.2/3.1, a flip angle of 10°, 2.6-mm sec-
tion thickness, an FOV of 300 mm, a matrix of 256 × 192,
and an acquisition time of 1 min 31 s) obtained before
and 91, 192, 273, 364, and 455 s after the rapid bolus in-
jection of Gd-DTPA.
Post-processing manipulation included the production
of subtraction, multiplanar reconstruction of sagittal
image, and maximum-intensity-projection (MIP) images.
Image analysis
Images were evaluated by a radiologist with 9 years of
experience in the field of evaluation of breast MRI.
Location was categorized into seven organs (liver, lung,
bone, mediastinum, pleural or chest wall, supraclavicular
LN, or other uncategorized location). Multiplicity was
defined as having more than one separate lesion with a
same imaging feature in the same organ. Signal intensity
(SI) on T1WI and T2WI, DWI, and ADC map was
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categorized into high, iso-, or low intensity compared
with surrounding normal tissue intensity.
Size of the lesion was measured as the longest diameter
in axial section on T2WI or contrast-enhanced T1WI.
Determination of malignancy
We concluded presence of a malignant lesion if it
were confirmed by pathologic examination. If patho-
logic examination was not made, we considered ma-
lignancy based on other diagnostic examinations and
follow-up imaging studies. CT, PET-CT, ultrasound,
and skeletal scintigraphy were used, and malignancy
was suggested if increased uptake on PET-CT corre-
lated in location corresponding with abnormal find-
ings on MRI or the lesions became larger during the
follow-up periods or decreased in size after chemo-
therapy or radiation treatment [15].
Statistical analysis
Malignancy of the extramammary findings was corre-
lated with the clinicopathologic findings and MRI im-
aging characteristics using univariate logistic regression
analysis. Pearson’s chi-square test was used to assess the
relationship between malignancy and each MRI imaging
characteristic or multiplicity. The data were analyzed
using the SPSS software version 21.0 (Statistical Package
for Social Sciences, SPSS, Chicago, IL, USA). Statistical
significance was defined as P < 0.05.
Results
A total of 109 patients was found to have 149 incidental
extramammary findings (Table 1). Incidental finding was
found in the bone (43/149, 28.9 %), liver (33/149, 22.1 %),
lung (32/149, 21.5 %), pleura or chest wall (15/149,
10.1 %), mediastinum (10/149, 6.7 %), supraclavicular LN
(9/149, 6.0 %), and other sites (6/149, 4.7 %). Total num-
ber of benign lesions was 80 (53.7 %), and malignancy was
69 (46.3 %). The most common site of malignant lesion
was the bone (30/69, 43.5 %) (Fig. 1). Other common sites
of malignant lesions were the lung (11/69, 15.9 %), pleura
or chest wall (8/69, 11.6 %), supraclavicular LN (8/69,
11.6 %), liver (7/69, 10.1 %), mediastinum (4/69, 5.8 %),
and other sites (1/69, 1.4 %). The site with the highest
malignancy rate was the supraclavicular LN with 88.9 %
(8/9), followed by bone malignancy, with a rate of 69.8 %
(30/43) (Fig. 1), pleura or chest wall 53.3 % (8/15) (Fig. 2),
lung 34.3 % (11/32), liver 21.2 % (7/33), mediastinum 40 %
(5/10), and others (1/7, 14.3 %).
The relevance of patient age and clinicopathologic find-
ings of breast cancer and the malignancy of the extramam-
mary findings is summarized in Table 2. Patient’s age had
no significant relevance (P = 0.569, odds ratio, OR = 0.99).
Larger tumor size (P = 0.006, OR = 1.37) (Fig. 2), existence
of LN metastasis (P = 0.000, OR = 3.99), existence of
distant metastasis (P = 0.000, OR = 32.33), and higher TNM
stage (I/II vs. III/IV, P = 0.000, OR = 19.18) had significant
relation with malignancy of the extramammary finding.
MRI imaging characteristics of the extramammary
findings between benign and malignancy are shown in
Table 3. Multiplicity of the finding (P = 0.000, OR =
5.13), iso-/low SI on T2WI (P = 0.028, OR = 0.46),
positive contrast enhancement (P = 0.000, OR = 7.39),
high SI on DWI (P = 0.049, OR = 8.18), and low SI on
ADC map (P = 0.000, OR = 33.70) were significantly
related to malignancy of the finding (Figs. 1, 2, and
3). Size of the finding (P = 0.159, OR = 0.88) and high
SI on T1WI (P = 0.574, OR = 0.82) have shown no sig-
nificant relation with the malignancy of the finding.
Most malignant extramammary findings showed high
intensity on DWI and low SI on ADC map (Table 4).
Discussion
Recently, multi-channel whole-body MR systems using
3-T MR became available and are known to have high
sensitivity for distant metastasis and detecting LN
involvement [8–10]. Accordingly, MRI can be useful for
detecting extramammary malignant lesions included in
the FOV of breast MRI, in addition to other benign
lesions. Our results reinforce the importance of extra-
mammary findings of breast MRI that had been noted in
an earlier study [13].
Overall, incidental extramammary findings were ob-
served in 155 (4.7 %) of 3296 dynamic contrast-
enhanced breast MRI exams. We have not counted the
same extramammary findings observed repeatedly on
follow-up studies, so the exact prevalence would be
4.8 % (n = 114) of 2361 patients. Nevertheless, the preva-
lence of our study was lower compared with other prior
studies, which reported prevalence as 9 % [12] and 17 %
[1]. Our study showed relatively low prevalence (49.5 %)
of malignancy (50/101) in patients examined for pre-
operative staging compared with a previous study that
Table 1 Incidence of extramammary findings according to
location
Location Benign Malignancy Malignancy
rate
Incidence
Bone 13 30 30/43 (69.8) 43 (28.9)
Liver 26 7 7/33 (21.2) 33 (22.1)
Lung 21 11 11/32 (34.3) 32 (21.5)
Pleura and chest wall 7 8 8/15 (53.3) 15 (10.1)
Mediastinum 6 4 4/10 (40.0) 10 (6.7)
Supraclavicular lymph
node
1 8 8/9 (88.8) 9 (6.0)
Other 6 1 1/7 (14.3) 6 (4.7)
Total 80 69 69/149 (46.3) 149
Numbers in parentheses are percentage
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showed 81 % prevalence [12]. One factor might be that
we have excluded the number of the same findings on
follow-up studies. Furthermore, we only retrospectively
reviewed the radiology reports, which may have ignored
trivial and obvious benign lesions.
Common sites of malignancy were the supraclavicular
LN, bone, lung, pleura or chest wall, and mediastinum,
ordered by frequency. This corresponds well with a prior
study of common breast cancer metastasis sites, which
are known to be the bone, lung, liver, pleura, periton-
eum, and others [16] or the bone, lung/pleural, chest
wall/skin, nodes, liver, and others [17]. Our study also
has results similar to other studies of incidental extra-
mammary findings [1, 12, 13]. The liver was the most
Fig. 1 Early detection of bone metastases with MRI. Case of a 43-year-old female patient diagnosed with stage I breast cancer. Multiple
sternum lesions (arrow) shown as hyperintense nodules on T1WI (a), T2WI (b), with positive contrast enhancement (c), and multiplicity (d)
on contrast-enhanced T1WI. On initial PET/CT (e), no definite uptake was noted, but 7 months later, FDG uptake was seen on follow-up
PET/CT (f)
Fig. 2 Multiple pleural metastases. Pre-operative breast MRI of a 46-year-old female patient with confirmed right breast cancer on biopsy. Multiple
pleural nodules (arrows) showing contrast enhancement (a), isointense on T2WI (b), and definite diffusion restriction (c, d). These lesions were
confirmed as pleural metastases in follow-up PET/CT and chest CT
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frequent site of benign lesions in our study. Former
studies also showed highest prevalence of incidental
extramammary findings in the liver, with low malignancy
rate [1, 12–14].
Our study showed that the (1. higher TNM stage),
(2. bigger tumor size), (3. existence of LN metastasis),
(4. existence of distant metastasis) are all significantly
related to malignancy of extrammamary finding. This
is consistent with our understanding of cancer
mechanism.
Our study also showed that multiplicity, positive con-
trast enhancement, iso- or low SI on T2WI, high SI on
DWI, and low SI on ADC map are significantly related
to malignancy of extramammary findings. Multiplicity is
a common feature of hematogenous metastasis [18, 19],
and multiplicity raises the suspicion for malignancy in
Table 2 Univariate logistic regression analysis of clinicopathologic characteristics of breast cancer for differentiating malignancy






Odds ratio (95 % CI) P value
Age 56.29 ± 12.68 54.97 ± 15.45 0.99 (0.97, 1.01) 0.569
Tumor size (cm) 2.69 ± 1.89 4.23 ± 2.58 1.37 (1.09, 1.71) 0.006
Lymph node metastasis 23/66 (34.8) 16/26 (61.5) 3.99 (1.99, 8.00) 0.000
Distant metastasis 7/71 (9.9) 48/62 (77.4) 32.33 (12.13, 86.14) 0.000
TNM stage (I/II vs. III/VI) 19.18 (7.74, 47.54) 0.000
Stage I 23/71 (32.4) 2/62 (3.2)
Stage II 30/71 (42.2) 6/62 (9.7)
Stage III 13/71 (18.3) 7/62 (11.3)
Stage IV 5/71 (7.0) 47/62 (75.8)
CI confidence intervals








Odds ratio (95 % CI) P value
Multiplicity 149 5.13 (2.54, 10.37) 0.000
Single 76 55/76 (72.4) 21/76 (27.6)
Multiple 71 24/71 (33.8) 47/71 (66.2)
Size (cm) 149 2.47 ± 1.98 1.99 ± 2.07 0.88 (0.74, 1.04) 0.159
T1 signal intensity 141 0.82 (0.41, 1.64) 0.574
Hyperintense 52 30/52 (57.7) 22/52 (42.3)
Iso/hypointense 89 47/89 (51.6) 42/89 (46.1)
T2 signal intensity 138 0.46 (0.23, 0.92) 0.028
Hyperintense 86 53/86 (61.6) 33/86 (38.4)
Iso/hypointense 52 22/53 (42.3) 30/52 (57.7)
Contrast enhancement 146 7.39 (2.86, 19.08) 0.000
Presence 106 46/106 (43.4) 60/106 (56.6)
Absence 40 34/40 (85.0) 6/40 (15.0)
DWI signal intensity 91 8.18 (1.00, 67.03) 0.049
Hyperintense 80 44/80 (55.0) 36/80 (45.0)
Iso/hypointense 11 10/11 (90.9) 1/11 (9.1)
Apparent diffusion coefficient map 81 38.70 (10.76, 139.20) 0.000
Hyperintense 32 5/32 (15.6) 27/32 (84.4)
Iso/hypointense 49 43/49 (87.8) 6/49 (12.2)
CI confidence intervals, DWI diffusion-weighted imaging
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lung nodules [18]. Although the probability of a hepatic
lesion being malignant is less than 20 % [14, 20], further
studies are required when suspicious characteristics are
observed on the MRI, such as the presence of multipli-
city, indistinct margins, or rim enhancement [21]. Our
study showed that the positive enhancement of the liver
nodule was related to malignant finding (P = 0.003).
However, multiplicity of liver nodules showed no signifi-
cant relationship with malignancy (P = 0.174).
Some previous articles mentioned that bone metastasis
of breast cancer is commonly observed as high SI
on T2WI [14]. Another study showed that mixed
characteristics on T2WI [22] are significantly related to
bone metastasis of breast cancer, and our study also
showed similar results: high SI 37 %, iso- to low SI 63 %.
DWI is well known for its high sensitivity and specifi-
city of detecting metastasis and malignancies [23–26].
Our study also showed that metastatic lesions mostly
show high SI on DWI with low SI on ADC map
(Table 4). Our study showed significance of SI on ADC
map in comparison with that on DWI by means of
determining malignancy of incidental findings, a com-
parison that was never studied before, to our knowledge.
Our findings demonstrated effectiveness of DWI in
determining malignancy of incidental finding. One of
our cases showed that DWI can detect small metastatic
lesions before PET-CT, as shown in Fig. 3. However, it is
also important to check other features because DWI
alone shows low specificity for the detection of regional
or metastatic lesions [24].
There are several limitations to this study. First, it was
a retrospective study. Second, we only searched images
through radiologic reports; thus, the possibility exists
that many incidental findings were not counted in our
study because they were not mentioned in the radiologic
report due to low significance or benignity. Third, only
two cases were confirmed by pathologic evaluation, and
67 other cases were considered metastatic on the basis
of other follow-up confirmation examinations. We
Fig. 3 Benign liver mass. Case of a 49-year-old female patient with two lesions. A solid mass (arrow) with a small cyst (arrow head) on the posterior
aspect in is seen in the right hepatic lobe. The lesion shows hypointense on T1WI (a) and T2WI (b), with no definite contrast enhancement (c), and no
diffusion restriction (d, e). This was thought to be a dense calcific benign mass, and additional follow-up MRIs and CTs for 2 years showed no interval
change, so we were able to confirm it as a benign lesion
Table 4 Characteristics of malignant extramammary findings on
diffuse-weighted images







Bone 17 1 13 3
Liver 3 0 3 0
Lung 8 0 6 1
Pleura and chest wall 5 0 3 2
Mediastinum 2 0 1 0
Supraclavicular lymph
node
0 0 0 0
Other 1 0 1 0
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believe additional studies with prospective design and
pathologic confirmation will give more accurate infor-
mation for determining malignancy.
Conclusions
In conclusion, incidental extramammary findings on
breast MRI should not be neglected. A significant por-
tion of the findings can be malignant, and that could
change the diagnostic work-up or treatment plan. In
addition to imaging findings such as multiplicity, SI on
T2WI and contrast enhancement on T1WI, DWI, and
ADC map can be reliable and effective tool to determine
malignancy.
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